Thor Halfdanarson: Need info on the rare acinar cell carcinoma of the pancreas?
Thor Halfdanarson, Vice President of the North American Neuroendocrine Tumor Society, shared a recent article by Zishuo Ian Hu et al, on X, adding:
“Need info on the rare acinar cell carcinoma of the pancreas (PACC)?
48% with resectable tumors and 5-year Overall Survival following resection was 72%.
Outcomes of patients with metastatic and unresectable PACC are poor, 5-year Overall Survival of 21 percent, seemingly better than PDAC.”
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients
Authors: Zishuo Ian Hu, Dean C. Pavlick, Jeffrey S. Ross, Sunyoung S. Lee, Madhulika Eluri, Milind Javle.
“The majority were pure PACC but 17 percent PACC/NEC.
Objective Response Rate 73 percent with chemo + RT in localized disease.
Progression-free survival and Overall Survival 108 and 27.3 mos in metastatic disease on FOLFIRINOX.
Molecular alterations common, most commonly HRD, both somatic and germline.”
More posts featuring Thor Halfdanarson.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023